Skip to main content


Tuesday 11 June: 7:30–9:30


Presenters: Rajiv Agarwal, MD, MBBS, FASN, BRCU; Meg Jardine, MD, PhD; Bruce Neal, MB, ChB, PhD; Kenneth W. Mahaffey, MD, PhD; Bernard Zinman, CM, MD.

The CREDENCE primary findings, published in April this year, showed that the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin significantly reduced the risk for renal failure and cardiovascular disease in people with type 2 diabetes and chronic kidney disease.

The researchers will present these results in full, along with an analysis of outcomes by baseline cardiovascular disease.

More on the CREDENCE trial


Update 06-12-2019CARMELINA findings confirmed in highest CV risk subgroups

Presenters: Steven E. Kahn, MB, ChB; Nikolaus Marx, MD, FESC, FAHA; Darren K. McGuire, MD, MHSc; Robert D. Toto, MD; Christoph Wanner, MD; Mark E. Cooper, MBBS, PhD.

The CARMELINA trial was powered to detect cardioprotective effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, but it showed only that it was noninferior to placebo. The researchers will present new renal analyses at this year's ADA.

The CAROLINA trial, also being presented at ADA, is reporting the results of a head-to-head comparison of the cardiovascular safety/efficacy of linagliptin and glimepiride.

More on the CARMELINA trial